ABIFINA
CONTATO
ASSOCIE-SE
LOGIN
  • Sobre
    • Quem somos
    • Código de Conduta Ética
    • Comitês
    • Estatuto Social
    • Estrutura organizacional
    • Galeria dos Presidentes
    • História
    • Segmentos da Química Fina
  • Prêmios
    • Prêmio Alcebíades de Mendonça Athayde
    • Prêmio Denis Barbosa
  • Associados
  • Notícias
    • ABIFINA na mídia
    • Associado em foco
    • Acontece na ABIFINA
    • Outras Notícias
  • Eventos
  • Produtos e serviços
    • ABIFINA Divulga
    • Clipping Diário de Notícias
    • Estatísticas
    • Centro de Monitoramento de Patentes
      • MPP Agro
      • MPP BIO
      • MPP Cannabis
      • MPP FDA
      • MPP FDA Biossimilares
      • MPP Saúde Animal
      • MPP SUS
    • Observatório de Ilegais
    • Panorama Regulatório Internacional
    • Propriedade Intelectual
      • Processo Administrativo de Nulidade (PAN)
      • Redação de Patentes
      • Relatórios de Patenteabilidade
      • Subsídios Técnicos
    • Resumo Semanal
  • Publicações
    • Revista FACTO
    • Todas as publicações
CONTATO

Repositório Covid-19

13/04/2022

PipeCoV: a pipeline for SARS-CoV-2 genome assembly, annotation and variant identification

Since the identification of the novel coronavirus (SARS-CoV-2), the scientific community has made a huge effort to understand the virus...

13/04/2022

Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting

Abstract

BACKGROUND

With large waves of infection driven by the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus 2...

11/04/2022

Vaccine effectiveness against SARS-CoV-2 infection and severe outcomes among individuals with immune-mediated inflammatory diseases tested between March 1 and Nov 22, 2021, in Ontario, Canada: a population-based analysis

We estimated COVID-19 vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes among individuals with immune-mediated inflammatory diseases in Ontario,...

09/04/2022

Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)

Multiple vaccine candidates against COVID-19 are currently being evaluated. We evaluate the safety and immunogenicity protein of a novel SARS-CoV-2...

08/04/2022

COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study

With the surge of new SARS-CoV-2 variants, countries have begun offering COVID-19 vaccine booster doses to high-risk groups and, more...

08/04/2022

Pathogenicity of SARS-CoV-2 Omicron (R346K) variant in Syrian hamsters and its cross-neutralization with different variants of concern

SARS-CoV-2 Omicron variant is rampantly spreading across the globe. We assessed the pathogenicity and immune response generated by BA.1.1 sub-lineage...

07/04/2022

Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines

SARS-CoV-2 Omicron variant evades immunity from past infection or vaccination and is associated with a greater risk of reinfection among...

06/04/2022

FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation

SARS-CoV-2 can cause acute respiratory distress and death in some patients1. Although severe COVID-19 is linked to substantial inflammation, how...

05/04/2022

Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak is posing a serious public health threat worldwide in the form of...

05/04/2022

SARS-CoV-2 BA.1 variant is neutralized by vaccine booster–elicited serum but evades most convalescent serum and therapeutic antibodies

As the SARS-CoV-2 Omicron BA.1 variant spreads across the world, the degree to which vaccine- and infection-elicited antibodies conferred protection...

05/04/2022

David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors

Anti-SARS-CoV-2 monoclonal antibodies and vaccines have shown improvement in lowering viral burden and hospitalization. However, emerging SARS-CoV-2 variants contain neutralizing...

05/04/2022

Characterisation and natural progression of SARS-CoV-2 infection in ferrets

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the infectious disease COVID-19, which has rapidly become an international...

  • « anterior
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 38
  • 39
  • 40
  • 41
  • próxima »
  • Sobre
  • Associados
  • Notícias
  • Eventos
  • Estatísticas
  • Publicações
  • Contato
  • Política de Privacidade
Av. Churchill, 129 • Sala 1201 • Centro • Rio de Janeiro • RJ
+55 21 3125-1400 [email protected]

Todos os direitos reservados © 2025 - ABIFINA

Desenvolvido por Conceito Comunicação Integrada
Login
Esqueci a senha